论文部分内容阅读
虽然已有关于在输血后非甲非乙肝炎(PTH NANB)中检测抗-C100-3(抗HCV非结构蛋白抗体)和抗-P22(抗HCV核心蛋白抗体)的报道,但是它们的远期临床意义尚未确定。作者对长期随访表现为不同临床结局的PTH NANB患者的连续血清标本检测抗-C100-3和抗-P22,并用套式聚合酶链反应检测血清中HCV RNA,以评价抗-C100-3和抗P22的临床意义。 研究对象为1975～1986年间诊断为PTHNANB的18例患者,筛选条件为:(1)在PTH发生之前无肝病史、毒品成瘾史和纹
Although reports on detection of anti-C100-3 (anti-HCV non-structural protein antibody) and anti-P22 (anti-HCV core protein antibody) in non-A, non-B hepatitis after transfusion (PTH NANB) have been reported, their long- Clinical significance has not been determined. The authors tested anti-C100-3 and anti-P22 in serial sera of patients with PTH NANB who had long-term follow-up of clinically different clinical outcomes and examined for serum HCV RNA using nested polymerase chain reaction to assess anti-C100-3 and anti P22 clinical significance. The subjects were 18 patients diagnosed as PTHNANB from 1975 to 1986, screening conditions were: (1) no history of liver disease, drug addiction history and pattern before PTH